Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Earle Burgess"'
Autor:
Sarmad Sadeghi, David Quinn, Tanya Dorff, Sumanta Pal, Susan Groshen, Denice Tsao-Wei, Rahul Parikh, Michael Devitt, Mamta Parikh, Alexandra Jackovich, Nora Ruel, Nicholas Vogelzang, Earle Burgess, Imran Siddiqi, Inderbir S. Gill, Primo N. Lara, Robert Dreicer, Parkash S. Gill
Publikováno v:
Journal of Clinical Oncology. 41:640-650
PURPOSE Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed death ligand 1 antibodies have low response rates and thus there exists a ma
Autor:
Matthew Galsky, Peter O’Donnell, Earle Burgess, Michiel Van der Heijden, Laurence Krieger, Andrea Necchi, Evan Yu, Nobuaki Matsubara, Matthew Campbell, Saikrishna Gadde, Jeanny Aragon-Ching, Vadim Koshkin, Wei Zhang, Kevin Sokolowski, Thomas Powles
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Brieuc Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Gwenaelle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz, Gyorgy Bodoky, Tibor Csoszi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasiliy Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Enrique Grande, Teresa Alonso Gordoa, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Mustafa Ozdogan, Alison Birtle, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, Stephanie Graff, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Mannuel, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming
Publikováno v:
The lancet oncology
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alon
Autor:
James Kearns, Erin Donahue, Rupali Bose, Jason Zhu, Claud Grigg, Earle Burgess, Kris Gaston, Stephen Riggs, Justin Matulay, Peter Clark
Publikováno v:
Journal of Urology. 207
Autor:
Albert Jang, Ellen Jaeger, Grant Rauterkus, Alex Liberman, Isabelle Sussman, Malcolm Light, Minqi Huang, Charlotte Manogue, Sydney Caputo, Patrick Miller, Brian Lewis, Jodi Layton, Oliver Sartor, Earle Burgess, Tiffany Farmer, Hayley Widden, Carrie Flippen, Alexey Aleshin, Claud Grigg, Pedro Barata
Publikováno v:
Journal of Urology. 207
Autor:
Earle Burgess, Chad Livasy, Sally Trufan, Jason Zhu, Hazel O'connor, Aaron Hartman, Peter Clark, Claud Grigg, Derek Raghavan
Publikováno v:
Molecular and clinical oncology. 16(5)
Biomarkers are needed in muscle-invasive bladder cancer (MIBC). We previously reported that high tumor aurora kinase (AURK) A expression identifies patients with MIBC with poor prognosis. Aberrant p53 expression has also been associated with poor out
Autor:
Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E Santiago-Walker, Manish Monga, Anne O'Hagan, Yohann Loriot, Scott Tagawa, Aude Flechon, Boris Alexeev, Sergey Varlamov, Robert Huddart, Earle Burgess, Arash Rezazadeh, Arlene Siefker-Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begona Mellado, Omi Parikh, Peter Schatteman, Stephane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio Scagliotti, Giovanni Schinzari, Jae Lyun Lee, Mikhail Shkolnik, Mark Fleming, Monica Joshi, Peter O'Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, Remy Delva, Frederic Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, Cristina Cebotaru, Victor Moreno, Jose Luis Perez Gracia, Alvaro Pinto, Wen-Pin Su, Shian-Shiang Wang, John Hainsworth, Ian Schnadig, Sandhya Srinivas, Nicholas Vogelzang, Wolfgang Loidl, Johannes Meran, Marine Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, Susanne Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauss, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora Nanette Sternberg, Sun Young Rha, Iurie Bulat, Adel Izmailov, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, Maribel Saez, Isabel Syndikus, Kathryn Tarver, Leonard Appleman, John Burke, Nancy Dawson, Sharad Jain
Publikováno v:
The Lancet Oncology, Vol. 23, no.2, p. 248-258 (2022)
Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f518baf9decca47c67f21a5a6035817d
https://hdl.handle.net/2078.1/275404
https://hdl.handle.net/2078.1/275404
Autor:
Kim ES; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. edward.kim@carolinashealthcare.org., Bernstein D; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Hilsenbeck SG; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Chung CH; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Dicker AP; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Ersek JL; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Stein S; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Khuri FR; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Burgess E; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Hunt K; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Ivy P; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Bruinooge SS; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Meropol N; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Schilsky RL; Edward S. Kim, Jennifer L. Ersek, and Earle Burgess, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; David Bernstein, Suanna S. Bruinooge, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan G. Hilsenbeck, Dan L. Duncan Cancer Center, Baylor College of Medicine; Kelly Hunt, University of Texas MD Anderson Cancer Center, Houston, TX; Christine H. Chung, Johns Hopkins University School of Medicine, Baltimore; Percy Ivy, National Cancer Institute, Bethesda, MD; Adam P. Dicker, Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University, Philadelphia, PA; Steven Stein, Novartis, East Hanover, NJ; Fadlo R. Khuri, Winship Cancer Institute, Emory University, Atlanta, GA; and Neal Meropol, University Hospitals Case Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Sep 01; Vol. 33 (25), pp. 2815-20. Date of Electronic Publication: 2015 Jul 20.